Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Trade Groups Focus On GMP Compliance, R&D in 2014

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement industry trade groups’ 2014 goals include improving GMP compliance, defining “natural” and advancing research in the supplement space. Stakeholders await revised guidances on NDI notifications and on distinguishing liquid supplements from traditional beverages.

You may also be interested in...

Claims Emerge To Join “Natural” As Class Action Fodder

Claims a product is “natural,” health and prevention claims, “whole grain” and “made with” claims, all can put a firm at risk for a lawsuit, the Center for Science in the Public Interest warns. After climbing for five years in a row, class action lawsuits brought against food products dipped in 2013, but the decline may be short-lived.

Larger Nutritional Studies Needed To Fill Data Gap – HHS Panel

USPSTF recommends expanded research and innovative methods to explore the effects and complexities of nutrients. The panel says current research is insufficient to determine whether the use of multivitamins and single-ingredient dietary supplements help prevent CVD or cancer, and recommends against the use of beta-carotene or vitamin E supplements for prevention of the conditions.

FDA NDI Draft Is A Push For Tighter Supplement Regulation – Stakeholders

FDA proposed “a pretty crazy” NDI notification draft guidance, says attorney Wes Siegner, because “they think everything is an NDI.” Other stakeholders acknowledge FDA wants tighter regulation of the industry, but say writing and imposing rules for supplement manufacturing is a two-way street.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts